The profit after tax declined by 19 per cent year-on-year to Rs 76 crores
Read MoreThe company informed that its revenue reached Rs. 2,859 crores, reflecting a 10 per cent increase compared to the same period last year
Read MoreFocusing sharply on its core business resulted in a 68 per cent compound annual growth rate (CAGR), reducing adjusted negative EBITDA from Rs 162 crore to Rs 17 crore
Read MoreThe company's mission focuses on reducing avoidable blindness in India by developing affordable and portable ophthalmic screening devices
Read MoreFor the annual performance in FY24, HCG's revenue was Rs 19,121 million
Read MoreOn an yearly basis, gross profit for FY24 was Rs16,291 million, up 22 per cent from Rs 13,328 million in FY23
Read MoreIn Q4 FY24, JB Pharma recorded a revenue of Rs 862 crores, marking a 13 per cent increase from Rs 762 crores in Q4 FY23
Read MoreIn Q4 FY24, Mankind Pharma reported revenue from operations of Rs 2,441 Cr, marking a notable 19 per cent year-on-year (YoY) increase
Read More